Loading…
Reported covered position: Professional Staff, House E&C Committee to Cathy McMorris Rodgers (2021-22) & Greg Walden (2017-21); Leg. Asst., Rep. Greg Walden, 4/2015-1/2017; Leg. Asst., Rep. Jackie Walorski, 10/2013-4/2015; Leg. Asst., Rep. Devin Nunes, 10/2012-10/2013
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Choices for Stranded Passengers Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Further Consolidated Appropriations Act, 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHIESI USA, INC. via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Extension of Priority Review Vouchers in S 4583; HR 7384 the Creating Hope Reauthorization Act, HR 3433 Give Kids a Chance Act; FDA reforms to improve rare disease patient perspective input and flexibilities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| Alnylam Pharmaceuticals, Inc. |
| 5 |
| 2023–2024 |
| BIPARTISAN POLICY CENTER ACTION | 4 | 2023–2024 |
| ADVANCED CARE AT HOME (ACH) COALITION | 3 | 2024 |
| BRISTOL-MYERS SQUIBB | 3 | 2023 |
| CHIESI USA INC | 3 | 2024 |
| UNITEDHEALTH GROUP | 2 | 2023 |
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services; Better Mental Health Care, Lower Costs Drugs and Extenders Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Further Consolidated Appropriations Act, 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Further Consolidated Appropriations Act, 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, Issues related to patient access to rare disease therapies, HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 the Consolidated Appropriations Act of 2024
Living Donor Protection Act of 2023
Client: AMERICAN KIDNEY FUND · Firm: SPLITOAK STRATEGIES LLC
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384; Unknown causes of kidney disease
Living Donor Protection Act of 2023
Client: AMERICAN KIDNEY FUND · Firm: SPLITOAK STRATEGIES LLC
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384; Unknown causes of kidney disease; APOL1-Mediated Kidney Disease (AMKD)
Extension of Priority Review Vouchers in S 4583; HR 7384 the Creating Hope Reauthorization Act, HR 3433 Give Kids a Chance Act; FDA reforms to improve rare disease patient perspective input and flexibilities
PATIENT Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Consolidated Appropriations Act, 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services; Better Mental Health Care, Lower Costs Drugs and Extenders Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Consolidated Appropriations Act, 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Consolidated Appropriations Act, 2024
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement, Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P/CMS-1784-F); H.R.4366 - Consolidated Appropriations Act, 2024; S.3430, Better Mental Health Care, Lower Cost Drugs and Extenders Act; HR 5378, Lower Costs, More Transparency Act
Consolidated Appropriations Act, 2024
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Consolidated Appropriations Act, 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, Issues related to patient access to rare disease therapies, HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 the Consolidated Appropriations Act of 2024
To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the ultimate user, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
Support for Patients and Communities Reauthorization Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
Support for Patients and Communities Reauthorization Act
Client: BIPARTISAN POLICY CENTER ACTION · Firm: SPLITOAK STRATEGIES LLC
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); health care workforce improvements (the Senate Bipartisan Primary Care and Health Workforce Act); maternal health/maternal mortality
Support for Patients and Communities Reauthorization Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Lower Costs, More Transparency Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement, Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P/CMS-1784-F); H.R.4366 - Consolidated Appropriations Act, 2024; S.3430, Better Mental Health Care, Lower Cost Drugs and Extenders Act; HR 5378, Lower Costs, More Transparency Act
Lower Costs, More Transparency Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Lower Costs, More Transparency Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; and other workforce improvements
Lower Costs, More Transparency Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Joe Fiandra Access to Home Infusion Act of 2023
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Joe Fiandra Access to Home Infusion Act of 2023
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, Issues related to patient access to rare disease therapies, HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 the Consolidated Appropriations Act of 2024
Joe Fiandra Access to Home Infusion Act of 2023
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
Joe Fiandra Access to Home Infusion Act of 2023
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Seniors’ Access to Critical Medications Act of 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Seniors’ Access to Critical Medications Act of 2024
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
Creating Hope Reauthorization Act of 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
Extension of Priority Review Vouchers in S 4583; HR 7384 the Creating Hope Reauthorization Act, HR 3433 Give Kids a Chance Act; FDA reforms to improve rare disease patient perspective input and flexibilities
Creating Hope Reauthorization Act of 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
Extension of Priority Review Vouchers, HR 7384 the Creating Hope Reauthorization Act, FDA reforms to improve rare disease patient perspective input and flexibilities
Telehealth Modernization Act of 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Extending funding for Community Health Centers and preserving and enhancing federal reimbursement methodologies; ensuring continued access to telehealth services; HR 7623 Telehealth Modernization Act
Telehealth Modernization Act of 2024
Client: ADVANCED CARE AT HOME (ACH) COALITION · Firm: SPLITOAK STRATEGIES LLC
Extension of Acute Hospital Care at Home waiver program; Hospital Inpatient Services Modernization Act (H.R.8260/S.4350); AINS to H.R.7623, the Telehealth Modernization Act; AINS to H.R.8261, the Preserving Telehealth, Hospital, and Ambulance Access Act.
Hospital Inpatient Services Modernization Act
Client: ADVANCED CARE AT HOME (ACH) COALITION · Firm: SPLITOAK STRATEGIES LLC
Extension of Acute Hospital Care at Home waiver program; Hospital Inpatient Services Modernization Act (H.R.8260/S.4350); AINS to H.R.7623, the Telehealth Modernization Act; AINS to H.R.8261, the Preserving Telehealth, Hospital, and Ambulance Access Act.
Preserving Telehealth, Hospital, and Ambulance Access Act
Client: ADVANCED CARE AT HOME (ACH) COALITION · Firm: SPLITOAK STRATEGIES LLC
Extension of Acute Hospital Care at Home waiver program; Hospital Inpatient Services Modernization Act (H.R.8260/S.4350); AINS to H.R.7623, the Telehealth Modernization Act; AINS to H.R.8261, the Preserving Telehealth, Hospital, and Ambulance Access Act.
American Medical Innovation and Investment Act of 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
American Medical Innovation and Investment Act of 2024
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
Living Donor Protection Act of 2023
Client: AMERICAN KIDNEY FUND · Firm: SPLITOAK STRATEGIES LLC
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384; Unknown causes of kidney disease
Living Donor Protection Act of 2023
Client: AMERICAN KIDNEY FUND · Firm: SPLITOAK STRATEGIES LLC
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384; Unknown causes of kidney disease; APOL1-Mediated Kidney Disease (AMKD)
Bipartisan Primary Care and Health Workforce Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; and other workforce improvements
Bipartisan Primary Care and Health Workforce Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Bipartisan Primary Care and Health Workforce Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
SUPPORT for Patients and Communities Reauthorization Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
SUPPORT for Patients and Communities Reauthorization Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
SUPPORT for Patients and Communities Reauthorization Act
Client: BIPARTISAN POLICY CENTER ACTION · Firm: SPLITOAK STRATEGIES LLC
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); health care workforce improvements (the Senate Bipartisan Primary Care and Health Workforce Act); maternal health/maternal mortality
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement, Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P/CMS-1784-F); H.R.4366 - Consolidated Appropriations Act, 2024; S.3430, Better Mental Health Care, Lower Cost Drugs and Extenders Act; HR 5378, Lower Costs, More Transparency Act
MATE Improvement Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
Hospital Inpatient Services Modernization Act
Client: ADVANCED CARE AT HOME (ACH) COALITION · Firm: SPLITOAK STRATEGIES LLC
Extension of Acute Hospital Care at Home waiver program; Hospital Inpatient Services Modernization Act (H.R.8260/S.4350); AINS to H.R.7623, the Telehealth Modernization Act; AINS to H.R.8261, the Preserving Telehealth, Hospital, and Ambulance Access Act.
Creating Hope Reauthorization Act of 2024
Client: CHIESI USA, INC. · Firm: SPLITOAK STRATEGIES LLC
Extension of Priority Review Vouchers in S 4583; HR 7384 the Creating Hope Reauthorization Act, HR 3433 Give Kids a Chance Act; FDA reforms to improve rare disease patient perspective input and flexibilities
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Strengthening Community Care Act of 2023
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
HR 2559 To extend funding for Community Health Centers, the National Health Services Corps and for other purposes; Access to preventative health; HR____ to extend funding for the Teaching Health Center Graduate Medical Education Program; HR 2569 the Doctors of Community or the DOC Act
Strengthening Community Care Act of 2023
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
HR 2559 The Strengthening Community Care Act of 2023; Access to preventative health; HR 3561 the PATIENT Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps
Strengthening Community Care Act of 2023
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
HR 2559 The Strengthening Community Care Act of 2023; Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; Vaccine access for underserved populations
DOC Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
HR 2559 To extend funding for Community Health Centers, the National Health Services Corps and for other purposes; Access to preventative health; HR____ to extend funding for the Teaching Health Center Graduate Medical Education Program; HR 2569 the Doctors of Community or the DOC Act
Choices for Stranded Passengers Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R. 6363 Further Continuing Appropriation and Other Extensions Act of 2024
Choices for Stranded Passengers Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023
Living Donor Protection Act of 2023
Client: AMERICAN KIDNEY FUND · Firm: SPLITOAK STRATEGIES LLC
Living Donor Protection Act (H.R. 2923/S. 1384); public health education and outreach on kidney disease
Living Donor Protection Act of 2023
Client: AMERICAN KIDNEY FUND · Firm: SPLITOAK STRATEGIES LLC
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384
PATIENT Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023); Proposed rules from DEA on telehealth prescribing of controlled substances and buprenorphine.
PATIENT Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R. 6363 Further Continuing Appropriation and Other Extensions Act of 2024
PATIENT Act of 2023
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023
PATIENT Act of 2023
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
HR 2559 The Strengthening Community Care Act of 2023; Access to preventative health; HR 3561 the PATIENT Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps
Preparedness and Response Reauthorization Act
Client: BIPARTISAN POLICY CENTER ACTION · Firm: SPLITOAK STRATEGIES LLC
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R. 4531, the Support for Patients and Communities Reauthorization Act); health care workforce improvements; food as medicine; pandemic preparedness (including H.R. 4421, the Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4420, the Preparedness and Response Reauthorization Act, and S. 2333, Pandemic and All-Hazards Preparedness and Response Act); and Committee RFI response on CDC reform concepts
Preparing for All Hazards and Pathogens Reauthorization Act
Client: BIPARTISAN POLICY CENTER ACTION · Firm: SPLITOAK STRATEGIES LLC
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R. 4531, the Support for Patients and Communities Reauthorization Act); health care workforce improvements; food as medicine; pandemic preparedness (including H.R. 4421, the Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4420, the Preparedness and Response Reauthorization Act, and S. 2333, Pandemic and All-Hazards Preparedness and Response Act); and Committee RFI response on CDC reform concepts
To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the ultimate user, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the ultimate user, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R. 4531, the Support for Patients and Communities Reauthorization Act); alternative funding programs
To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the ultimate user, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R. 4531, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act; alternative funding programs
Support for Patients and Communities Reauthorization Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R. 6363 Further Continuing Appropriation and Other Extensions Act of 2024
Support for Patients and Communities Reauthorization Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R. 4531, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act; alternative funding programs
Support for Patients and Communities Reauthorization Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023
Support for Patients and Communities Reauthorization Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R. 4531, the Support for Patients and Communities Reauthorization Act); alternative funding programs
Support for Patients and Communities Reauthorization Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
Support for Patients and Communities Reauthorization Act
Client: BIPARTISAN POLICY CENTER ACTION · Firm: SPLITOAK STRATEGIES LLC
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R. 4531, the Support for Patients and Communities Reauthorization Act); health care workforce improvements; food as medicine; pandemic preparedness (including H.R. 4421, the Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4420, the Preparedness and Response Reauthorization Act, and S. 2333, Pandemic and All-Hazards Preparedness and Response Act); and Committee RFI response on CDC reform concepts
Support for Patients and Communities Reauthorization Act
Client: BIPARTISAN POLICY CENTER ACTION · Firm: SPLITOAK STRATEGIES LLC
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); health care workforce improvements (the Senate Bipartisan Primary Care and Health Workforce Act); maternal health/maternal mortality
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB · Firm: SPLITOAK STRATEGIES LLC
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB · Firm: SPLITOAK STRATEGIES LLC
Value of prescription drugs and patient access Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Share the Savings with Seniors Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: SPLITOAK STRATEGIES LLC
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of Prescription drug provisions in H.R. 5376, Inflation Reduction Act
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB · Firm: SPLITOAK STRATEGIES LLC
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Lower Costs, More Transparency Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023
Lower Costs, More Transparency Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R. 6363 Further Continuing Appropriation and Other Extensions Act of 2024
Lower Costs, More Transparency Act
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement, Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P/CMS-1784-F); HR6363, Further Continuing Appropriations and Other Extensions Act of 2024; S.3430, Better Mental Health Care, Lower Cost Drugs and Extenders Act; HR 5378, Lower Costs, More Transparency Act
Lower Costs, More Transparency Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
HR 2559 The Strengthening Community Care Act of 2023; Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; Vaccine access for underserved populations
Lower Costs, More Transparency Act
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024; Vaccine access for underserved populations
Joe Fiandra Access to Home Infusion Act of 2023
Client: AMRYT PHARMA · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act
Joe Fiandra Access to Home Infusion Act of 2023
Client: AMRYT PHARMA · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Joe Fiandra Access to Home Infusion Act of 2023
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Joe Fiandra Access to Home Infusion Act of 2023
Client: AMRYT PHARMA · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Joe Fiandra Access to Home Infusion Act of 2023
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act)
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act)
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: SPLITOAK STRATEGIES LLC
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Further Continuing Appropriations and Other Extensions Act, 2024
Client: AMRYT PHARMA · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Further Continuing Appropriations and Other Extensions Act, 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services; Better Mental Health Care, Lower Costs Drugs and Extenders Act; HR 6363 Further Continuing Appropriations Appropriations and Other Extensions Act of 2024
Further Continuing Appropriations and Other Extensions Act, 2024
Client: NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS · Firm: SPLITOAK STRATEGIES LLC
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024; Vaccine access for underserved populations
Further Continuing Appropriations and Other Extensions Act, 2024
Client: AMERICAN ACADEMY OF FAMILY PHYSICIANS · Firm: SPLITOAK STRATEGIES LLC
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R. 6363 Further Continuing Appropriation and Other Extensions Act of 2024
ANHEUSER-BUSCH COMPANIES via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
Differentiate beer from cannabis; general policy regarding the regulation of the alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
Extending funding for Community Health Centers and preserving and enhancing federal reimbursement methodologies; ensuring continued access to telehealth services; HR 7623 Telehealth Modernization Act
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; and other workforce improvements
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED CARE AT HOME (ACH) COALITION via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
Extension of Acute Hospital Care at Home waiver program; Hospital Inpatient Services Modernization Act (H.R.8260/S.4350); AINS to H.R.7623, the Telehealth Modernization Act; AINS to H.R.8261, the Preserving Telehealth, Hospital, and Ambulance Access Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF FAMILY PHYSICIANS via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement; issues related to Centers for Medicare and Medicaid Innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-169, Inflation Reduction Act of 2022 Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-P)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KIDNEY FUND via SPLITOAK STRATEGIES LLC
2024 · second_quarter · Q2
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384; Unknown causes of kidney disease; APOL1-Mediated Kidney Disease (AMKD)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
Extension of Priority Review Vouchers, HR 7384 the Creating Hope Reauthorization Act, FDA reforms to improve rare disease patient perspective input and flexibilities
HR 5397 the Joe Fiandra Access to Home Infusion Act, Issues related to patient access to rare disease therapies, HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 the Consolidated Appropriations Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
Differentiate beer from cannabis; general policy regarding the regulation of the alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services; Better Mental Health Care, Lower Costs Drugs and Extenders Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 Consolidated Appropriations Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED CARE AT HOME (ACH) COALITION via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
Extension of Acute Hospital Care at Home waiver program; Discussion draft of Rep. Wenstrup/Rep. Blumenauer, Hospital Inpatient Services Modernization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF FAMILY PHYSICIANS via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement, Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P/CMS-1784-F); H.R.4366 - Consolidated Appropriations Act, 2024; S.3430, Better Mental Health Care, Lower Cost Drugs and Extenders Act; HR 5378, Lower Costs, More Transparency Act
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R.4366 - Consolidated Appropriations Act, 2024
ALNYLAM PHARMACEUTICALS, INC. via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KIDNEY FUND via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384; Unknown causes of kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIPARTISAN POLICY CENTER ACTION via SPLITOAK STRATEGIES LLC
2024 · first_quarter · Q1
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); health care workforce improvements (the Senate Bipartisan Primary Care and Health Workforce Act); maternal health/maternal mortality
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via SPLITOAK STRATEGIES LLC
2024 · first_quarter · RR
Rare disease and orphan drug access and process improvements to incorporate patient perspectives
ADVANCED CARE AT HOME (ACH) COALITION via SPLITOAK STRATEGIES LLC
2024 · first_quarter · RR
Issues related to extending the Acute Hospital Care at Home waivers and flexibilities; advancing a pathway for permanent coverage of advanced care at home services.
AMRYT PHARMA via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · 4T
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024; Vaccine access for underserved populations
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services; Better Mental Health Care, Lower Costs Drugs and Extenders Act; HR 6363 Further Continuing Appropriations Appropriations and Other Extensions Act of 2024
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
AMRYT PHARMA via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
Differentiate beer from cannabis; general policy regarding the regulation of the alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF FAMILY PHYSICIANS via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement, Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P/CMS-1784-F); HR6363, Further Continuing Appropriations and Other Extensions Act of 2024; S.3430, Better Mental Health Care, Lower Cost Drugs and Extenders Act; HR 5378, Lower Costs, More Transparency Act
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023 and S.3393; S.3550, MATE Improvement Act; H.R. 6363 Further Continuing Appropriation and Other Extensions Act of 2024
JOHNSON & JOHNSON SERVICES, INC. via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
SUPPORT Act reauthorization (H.R. 4490, and H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KIDNEY FUND via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
Research, education and public health surveillance of kidney disease; Living Donor Protection Act H.R.2923/S.1384
Filing targets: HOUSE OF REPRESENTATIVES
BIPARTISAN POLICY CENTER ACTION via SPLITOAK STRATEGIES LLC
2023 · fourth_quarter · Q4
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R.4531/S.3393, the Support for Patients and Communities Reauthorization Act); health care workforce improvements (the Senate Bipartisan Primary Care and Health Workforce Act); maternal health/maternal mortality
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMRYT PHARMA via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services
HR 2559 The Strengthening Community Care Act of 2023; Access to preventative health; HR 5378 The Lower Costs, More Transparency Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps; Bipartisan Primary Care and Health Workforce Act; S 2840 the Primary Care and Health Workforce Act; Vaccine access for underserved populations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
ANHEUSER-BUSCH COMPANIES via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
Differentiate beer from cannabis; general policy regarding the regulation of the alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
Value of prescription drugs and patient access Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES
AMERICAN ACADEMY OF FAMILY PHYSICIANS via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023, H.R.5378 - Lower Costs, More Transparency Act, and S.2840 -- Bipartisan Primary Care and Health Workforce Act; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023) and as amended in Suspension Print of H.R. 4531 -- The Support for Patients and Communities Reauthorization Act of 2023
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement; Medicare and Medicaid Programs, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies, Medicare Shared Savings Program Requirements (CMS-1784-P);
JOHNSON & JOHNSON SERVICES, INC. via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
SUPPORT Act reauthorization (H.R. 4490, and H.R. 4531, the Support for Patients and Communities Reauthorization Act); prescription drug shortages of behavioral health medications with quotas subject to the Controlled Substances Act; alternative funding programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
RNA interference scientific advancements; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KIDNEY FUND via SPLITOAK STRATEGIES LLC
2023 · third_quarter · Q3
Living Donor Protection Act (H.R. 2923/S. 1384); public health education and outreach on kidney disease
Filing targets: HOUSE OF REPRESENTATIVES
AMRYT PHARMA via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
Improve access to home infusion services
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
Differentiate beer from cannabis; general policy regarding the regulation of the alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
SUPPORT Act reauthorization (H.R. 4490, and H.R. 4531, the Support for Patients and Communities Reauthorization Act); alternative funding programs
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
HR 2559 The Strengthening Community Care Act of 2023; Access to preventative health; HR 3561 the PATIENT Act to extend funding for Community Health Centers, Teaching Health Centers GME and the National Health Service Corps
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF FAMILY PHYSICIANS via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program; adequate physician reimbursement
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC) --including H.R.3561 - PATIENT Act of 2023; implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023); Proposed rules from DEA on telehealth prescribing of controlled substances and buprenorphine.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
UNITEDHEALTH GROUP via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
Value of coordination and management in providing high quality, efficient health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
RNA interference scientific advancements; differentiation of genetically-targeted therapies; S.476, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KIDNEY FUND via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
Living Donor Protection Act
Filing targets: HOUSE OF REPRESENTATIVES
BIPARTISAN POLICY CENTER ACTION via SPLITOAK STRATEGIES LLC
2023 · second_quarter · Q2
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic (including H.R. 4531, the Support for Patients and Communities Reauthorization Act); health care workforce improvements; food as medicine; pandemic preparedness (including H.R. 4421, the Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4420, the Preparedness and Response Reauthorization Act, and S. 2333, Pandemic and All-Hazards Preparedness and Response Act); and Committee RFI response on CDC reform concepts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
Implementation of SUPPORT Act
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of Prescription drug provisions in H.R. 5376, Inflation Reduction Act
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF FAMILY PHYSICIANS via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
Improve integration of behavioral health and primary care; advance value-based care; address workforce shortages and improve data collection under Graduate Medical Education program
Value of primary care and family medicine; reauthorization of expiring public health provisions, including the Teaching Health Center Graduate Medical Education (THCGME) program and National Health Service Corps (NHSC); implementation of the Medication Access and Training Expansion (MATE) Act (as included in H.R. 2617, Consolidated Appropriations Act, 2023); Proposed rules from DEA on telehealth prescribing of controlled substances and buprenorphine.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
BRISTOL-MYERS SQUIBB via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
Differentiate beer from cannabis; general policy regarding the regulation of the alcohol industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMRYT PHARMA via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
The BENEFIT Act; the HEART Act; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
Expand access to behavioral health care services for patients in underserved communities enrolled in federal programs, including the improved integration of behavioral health and primary care; extending funding for Community Health Centers and preserving payment methodologies; ensuring continued access to telehealth services
HR 2559 To extend funding for Community Health Centers, the National Health Services Corps and for other purposes; Access to preventative health; HR____ to extend funding for the Teaching Health Center Graduate Medical Education Program; HR 2569 the Doctors of Community or the DOC Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITEDHEALTH GROUP via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
FY24 Advance Notice of Methodological Changes for Medicare Advantage; Value of coordination and management in providing high quality, efficient health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIPARTISAN POLICY CENTER ACTION via SPLITOAK STRATEGIES LLC
2023 · first_quarter · Q1
General health care issues related to behavioral health and integration with primary care and addressing the opioid epidemic; health care workforce improvements; food as medicine; COVID-19/pandemic preparedness; health care transparency issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE